维普期刊资源整合服务平台（V6.5）

31篇 您的检索式：作者名="Marcom PK"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	TBCRC 001: randomized phase II study of cetuximab in combina- tion with carboplatin in stage IV triple-negative breast can- cer 显示文摘	CAREY LA RUGO HS MARCOM PK	2012	Journal of Clinical Ontology Official Journal of the American Society of Clinical Oncology2012，30，30：	1
2	TBCRC 001:EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer显示文摘	Carey LA Rugo HS Marcom PK	2008	J Clin Oncol2008，26，151：	1
3	EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative breast cancer显示文摘	Carey LA Rugo HS Marcom PK	2008	J Clin Oncol2008，26，15：	1
4	TBCRC 001 : randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer 显示文摘	Carey LA Rugo HS Marcom PK	2012	J Clin Oncol2012，30，21：	1
5	A pilot study of pre- dictive markers of chemotherapy-related amenorrhea among pre- menopausal women with early stage breast cancer显示文摘	Anders C Marcom PK Peterson B	2008	Cancer Invest2008，26，28：	1
6	TBCRC 001:randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer显示文摘	Carey LA Rugo HS Marcom PK	2012	J Clin Oncol2012，30，21：	1
7	Trastuzumab and vinorelbine as first-line therapy for HER2-overex- pressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm显示文摘	Burstein H J Harris LN Marcom PK	2003	J Clin Oncol2003，21，15：	1
8	TBCRC 001:EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer显示文摘	Carey LA Rugo HS Marcom PK	2008	J Clin Oncol2008，26，15：	1
9	Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: muhicenter phase 11 trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm显示文摘	Burstein HJ Harris LN Marcom PK	2003	J Clin Oncol2003，21，15：	1
10	The combination of letrozole and trastuzamab as first or secondlinebiological therapy produces dura- ble responses in a subset of HER2 positive and ER positive advanced breast cancers显示文摘	Marcom PK Isaacs C Harris L	2007	Breast Cancer Res Treat2007，102，：	1
11	The combination of letro- zole and trastuzumab as first or second-line biological therapy pro- duces durable responses in a subset of HER2 positive and ER positive advanced breast cancers 显示文摘	Marcom PK Isaacs C Harris L	2007	Breast Cancer Res Treat2007，102，1：	1
12	TBCRC 001 : random- ized phase 1I study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer显示文摘	Carey LA Rugo HS Marcom PK	2012	J Clin Oncol2012，30，21：	1
13	TBCRC 001 : ran-domized phase II study of cetuximab in combination withcarboplatin in stage IV triple-negative breast cancer显示文摘	Carey LA Rugo HS Marcom PK	2012	JClin O卿/2012，30，21：	1
14	TBCRC 001 : EGFR inhibition with cetuximab in metastatic triple negative (basal -like) breast canc- er 显示文摘	Carey LA Mayer E Marcom PK	2007	Breast Cancer Res Treat2007，106，1：	1
15	TBCRC 001:randomized phase Ⅱ study of cetuximab in combination with carboplatin in stage Ⅳ triple-negative breast cancer显示文摘	Carey LA Ruqo HS Marcom PK		0，，21：	1
16	TBCRC 001:randomized phase II study of cetuximab in combination withcarboplatin in stage IV triple-negative breast cancer显示文摘	Carey LA Rugo HS Marcom PK	2012	J ClinOncol2012，30，21：	1
17	Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 显示文摘	Seidman AD Berry D Cirrincione C Harris L Muss H Marcom PK Gipson G Burstein H Lake D Shapiro CL Ungaro P Norton L Winer E Hudis C	2008	J Clin Oncol2008，6，10：	1
18	TBCRC001: EGFR inhibition with cetuximab in metastatic triple negative (basal-like) breast cancer 显示文摘	Carey LA Mayer E Marcom PK	2008	J Clin Oncol2008，26，6：	1
19	Changes in weight,body composition,and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy显示文摘	Demark-Wahnefried W Peterson BL Winer EP Marks L Aziz N Marcom PK		0，，：	1
20	Trastuzumab and vinorelbine as first-line therapy for HER-2-overexpressing metastatic breast cancer:multicenter phase II trial with clinical outcomes,analysis of serum tumor markers as predictive factors,and cardiac surveillance algorithm显示文摘	Burstein HJ Harris LN Marcom PK	2003	J Clin Oncol2003，21，：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示